July 18, 2019
Astellas Pharma has obtained exclusive rights to develop and commercialize US biotech Frequency Therapeutics’ regenerative hearing loss treatment FX-322 outside the US, the two companies said on July 17. Under the deal, the Japanese major will pay US$80 million upfront...read more